Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis

被引：0
|
作者：
Rule, Simon
Dreyling, Martin
Goy, Andre
Hess, Georg
Auer, Rebecca
Kahl, Brad S.
Hernandez-Rivas, Jose Angel
Londhe, Anil
Clow, Fong
Deshpande, Sanjay
Parisi, Lori
Wang, Michael
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
151
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Economic Evaluation for the US of Ibrutinib Versus Acalabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma
    Alrawashdh, Neda
    Alkhatib, Nimer
    McBride, Ali
    Persky, Daniel
    Abraham, Ivo
    BLOOD, 2018, 132
  • [22] SAFETY AND EFFICACY OF IRON CHELATION THERAPY WITH DEFERASIROX IN PATIENTS WITH SICKLE CELL DISEASE: 3.5-YEAR FOLLOW-UP
    Vichinsky, E.
    Coates, T.
    Thompson, A. A.
    Bernaudin, F.
    Lagrone, D.
    Dong, V.
    Heeney, M. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 78 - 78
  • [23] A 3.5-year follow-up of an unusual case of rampant caries during clear aligner treatment
    Wang, Gengru
    Fang, Dongdong
    Yin, Xinqin
    Flores-Mir, Carlos
    AUSTRALASIAN ORTHODONTIC JOURNAL, 2023, 39 (01): : 171 - 182
  • [24] Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis
    Noy, Ariela
    de Vos, Sven
    Coleman, Morton
    Martin, Peter
    Flowers, Christopher R.
    Thieblemont, Catherine
    Morschhauser, Franck
    Collins, Graham P.
    Shuo, Ma
    Peles, Shachar
    Smith, Stephen D.
    Barrientos, Jacqueline C.
    Chong, Elizabeth
    Wu, Shiquan
    Cheung, Leo W-K
    Kwei, Kevin
    Hauns, Bernhard
    Arango-Hisijara, Israel
    Chen, Robert
    BLOOD ADVANCES, 2020, 4 (22) : 5773 - 5784
  • [25] A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma
    Martin, Peter
    Goy, Andre
    Ramchandren, Radhakrishnan
    Ferrante, Lucille
    Londhe, Anil
    McGowan, Tracy
    Bartlett, Nancy L.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (04) : 1027 - 1030
  • [26] REAL-WORLD TREATMENT OUTCOMES AMONG RELAPSED/REFRACTORY PATIENTS WITH MANTLE CELL LYMPHOMA TREATED WITH IBRUTINIB OR ACALABRUTINIB
    Crawford, S.
    Lafeuille, M. H.
    Emond, B.
    Harb, D.
    Voladarsky, R.
    Chen, N.
    Karve, S.
    VALUE IN HEALTH, 2023, 26 (06) : S403 - S403
  • [27] One year follow-up of ZUMA-2, the multicenter, registrational study of KTE-X19 in patients with relapsed/Refractory mantle cell lymphoma
    Wang, Michael L.
    Munoz, Javier
    Goy, Andre
    Locke, Frederick L.
    Jacobson, Caron A.
    Hill, Brian T.
    Timmerman, John M.
    Holmes, Houston
    Jaglowski, Samantha
    Flinn, Ian W.
    McSweeney, Peter A.
    Miklos, David B.
    Pagel, John M.
    Kersten, Marie Jose
    Milpied, Noel
    Fung, Henry C. H.
    Topp, Max S.
    Houot, Roch
    Beitinjaneh, Amer
    Peng, Weimin
    Zheng, Lianqing
    Rossi, John M.
    Murugappan, Swaminathan
    Kloos, Ioana
    Reagan, Patrick M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 42 - 43
  • [28] Effectiveness and Safety of Ibrutinib in Patients with Mantle Cell Lymphoma (MCL) in Belgian Routine Clinical Practice: 3-Year Follow-up
    Vergote, Vibeke
    Snauwaert, Sylvia
    Saevels, Kirsten
    De Beleyr, Birgit
    Lahaye, Marjolein
    Maes, Ariane
    Demuynck, Hilde
    Debussche, Sarah
    Andre, Marc
    BLOOD, 2022, 140 : 3661 - 3662
  • [29] Predictors of physical activity change during adolescence: a 3.5-year follow-up
    Dumith, Samuel C.
    Gigante, Denise P.
    Domingues, Marlos R.
    Hallal, Pedro C.
    Menezes, Ana M. B.
    Kohl, Harold W., III
    PUBLIC HEALTH NUTRITION, 2012, 15 (12) : 2237 - 2245
  • [30] Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma
    Tam, Constantine S.
    Opat, Stephen
    Simpson, David
    Cull, Gavin
    Munoz, Javier
    Phillips, Tycel J.
    Kim, Won Seog
    Rule, Simon
    Atwal, Siminder Kaur
    Wei, Rachel
    Novotny, William
    Huang, Jane
    Wang, Michael
    Trotman, Judith
    BLOOD ADVANCES, 2021, 5 (12) : 2577 - 2585
12345